CNSide Diagnostics
Tracked across 1 events · 6 articles · First seen Sep 10, 2026 · Last active Sep 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Cerenome, Inc. (Nasdaq: CNSY), a clinical-stage CNS oncology company, announced on September 10, 2026 that it entered into a financing agreement with 3i, LP for a senior secured facility of up to $20 million with…
Impact: CNSide Diagnostics, the wholly owned Cerenome subsidiary, is the primary beneficiary of the financing as proceeds support scale-up of its CNSide cerebrospinal fluid assay platform.
Sep 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track CNSide Diagnostics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard